Tempus AI has reported impressive growth, but some of the volatile quarterly numbers have chased off aggressive investors.

Tempus AI announces a multi-year collaboration with AstraZeneca and Pathos AI to build a multimodal foundation model in oncology. Tempus says the collaboration includes $200 million in data ...

Shares of Tempus AI (NASDAQ: TEM) were skyrocketing 16.5% higher as of 10:39 a.m. ET on Wednesday. The big gain came after the healthcare artificial intelligence (AI) company announced a multiyear ...

CHICAGO - Tempus AI, Inc. (NASDAQ: TEM), a leader in AI-driven precision medicine with a market capitalization of $9.15 billion, announced the launch of Tempus Loop, a new platform designed to ...

Tempus AI (TEM) has seen a significant surge on Wednesday, with its stock climbing 14.62% in just one day. The significant boost in TEM stock followed the announcement of a multiyear collaboration ...

Tempus AI, Inc. TEM is scheduled to report first-quarter fiscal 2025 results on May 6. In the last reported quarter, the company’s adjusted loss of 18 cents was wider than the Zacks Consensus Estimate ...